Research Studies

Apretude is the first and only long-acting injectable HIV prevention medication (PrEP) given once every other month via intramuscular injection. Apretude is a brand name version of extended release cabotegravir. It is FDA approved for people who are HIV negative and want to reduce their risk of contracting HIV.

The Beyond Study is a research study administered by Bridge HIV in partnership with Lyon-Martin Community Health Services with the aim of increasing access to Apretude for Transgender and Non-Binary people. The study is for Transgender and Non-Binary People who are HIV negative, over the age of 18, and want to try Apretude to reduce the risk of contracting HIV.